Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells
about
Transcriptional regulation of the human asparagine synthetase gene by carbohydrate availabilityPharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapyMultiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cellsAsparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cellsComparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines.Targeted metabolomic analysis of amino acid response to L-asparaginase in adherent cellsAsparagine synthetase: regulation by cell stress and involvement in tumor biologyAsparagine synthetase chemotherapy.An inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line.A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity.Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.Establishment of real-time polymerase chain reaction method for quantitative analysis of asparagine synthetase expressionATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia.Development of an ELISA to detect circulating anti-asparaginase antibodies in dogs with lymphoid neoplasia treated with Escherichia coli l-asparaginase.Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinomaInhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.First-line treatment of acute lymphoblastic leukemia with pegasparaginase.Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity.Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell linesSafety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.HepG2/C3A cells respond to cysteine deprivation by induction of the amino acid deprivation/integrated stress response pathway.Glutamine availability up-regulates expression of the amino acid transporter protein ASCT2 in HepG2 cells and stimulates the ASCT2 promoter.The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation.Characterization of a novel variant in siblings with Asparagine Synthetase Deficiency.Asparagine synthetase expression is associated with the sensitivity to asparaginase in extranodal natural killer/T-cell lymphoma in vivo and in vitroInhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response
P2860
Q22009073-2D4A0212-F3A5-4529-8AE8-AA6555554BDAQ28083449-8DBB548F-E671-498F-BC0E-5E709B57A5CEQ28345200-07D86233-139A-4DAC-A1C7-B273EB4D95F9Q28367265-D4693AF1-38AB-4411-8CC4-396836CE094FQ33701864-0033C3C2-5D53-438B-99A4-064104E1FD4CQ33718822-559F45FA-9849-4FAC-A800-FC327621B259Q34011217-C2E4C4EA-B0F2-4EBC-BB43-19CF61C7BED3Q34091338-45C9C302-AAA9-49D2-968F-80AAB738E9E3Q34327474-340489D9-5042-455A-9701-E3F1D3054490Q34535185-3392F30A-B3A1-403C-9B0B-D656BD13A1BDQ34653242-9C10B546-DFB6-42A6-A4B7-1D411B2DC2E8Q34989475-FA809A18-B6E4-4EB6-94A1-1A3445CB9582Q35677647-560E3664-0F09-41C6-B067-05DDC4C60480Q35790343-931E642F-CB01-49A5-8D17-661DD6A26498Q35930217-79493BF1-CAD7-4D4F-BAED-6CB863588007Q36739211-B6957D71-3E5B-40E6-89E9-8FEE39D823D8Q37003403-3A543606-F3F5-42B6-8650-1705F5AD6354Q37311260-21E26404-ED15-4D2B-8F11-8769727CCCFEQ37586935-BE225FA9-5F34-4E64-A0ED-8A96EA0BC29CQ37824564-3BCDD346-13D3-4A3E-8394-7B2EC3652276Q38248280-8134367C-C9C2-4074-9E84-EB699FCFBD2FQ38915906-AB2C87E1-9475-4AF7-974F-6351C32B58E9Q39194553-2FC10161-24FE-483D-8921-2325F7814823Q40011352-1ED624C6-60A5-4F81-87E7-FE382BC3D711Q40549715-ADC5A00A-C9BB-48EC-858D-C34C537EABB3Q41465002-738F69CF-9B50-41D6-8957-417EF8EF6F6DQ47253293-57BA4591-DFF4-4B8E-898A-3CA0EA1BDA60Q57817707-9EB1A887-6C89-44DD-9CF4-7B1D162B49C3Q57998597-828C9C3B-2B1D-459F-9D0E-5B84E3EFE5A9
P2860
Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells
description
1997 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մայիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1997
@ast
im Mai 1997 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1997/05/01)
@sk
vědecký článek publikovaný v roce 1997
@cs
wetenschappelijk artikel (gepubliceerd op 1997/05/01)
@nl
наукова стаття, опублікована в травні 1997
@uk
مقالة علمية (نشرت في مايو 1997)
@ar
name
Amino acid control of asparagi ...... stance in human leukemia cells
@ast
Amino acid control of asparagi ...... stance in human leukemia cells
@en
Amino acid control of asparagi ...... stance in human leukemia cells
@nl
type
label
Amino acid control of asparagi ...... stance in human leukemia cells
@ast
Amino acid control of asparagi ...... stance in human leukemia cells
@en
Amino acid control of asparagi ...... stance in human leukemia cells
@nl
prefLabel
Amino acid control of asparagi ...... stance in human leukemia cells
@ast
Amino acid control of asparagi ...... stance in human leukemia cells
@en
Amino acid control of asparagi ...... stance in human leukemia cells
@nl
P2093
P1476
Amino acid control of asparagi ...... stance in human leukemia cells
@en
P2093
D. A. Moraga Amador
M. S. Kilberg
R. G. Hutson
S. M. Schuster
P304
C1691–1699
P356
10.1152/AJPCELL.1997.272.5.C1691
P407
P433
P577
1997-05-01T00:00:00Z